| | Total number of patients | 41 | | Sex | Male: 12 (12/41, 29.2%) | | Female: 29 (29/41, 70.7%) | | Female-to-male ratio: 2.4 : 1 | | Median age | 60 years (age range: 34-85 years) | | Primary tumor location | Gallbladder | | Tumor site | Fundus: 16 (16/29, 55.2%) | | Body: 5 (7/29, 24.1%) | | Neck: 4 (4/29, 13.8%) | | Fundus and body: 2 (2/29, 6.9%) | | Metastatic site | Lymph nodes: 15 (15/41, 36.6%) | | Liver: 17 (17/41, 41.5%) | | Duodenum: 1 (1/41, 2.4%) | | Bone: 1 (1/41, 2.4%) | | Presenting symptoms | Abdominal pain: 22 (22/35, 62.9%) | | Fever: 2 (2/35, 5.7%) | | Back pain: 3 (3/35, 8.5%) | | Asymptomatic: 7 (7/35, 20.0%) | | Anorexia: 1 (1/35, 2.9%) | | Morphology | Protruding: 27 (27/36, 75.0%) | | Infiltrative: 9 (9/36, 25.0%) | | Histopathology of the neuroendocrine component | SCC: 9 (9/41, 22.0%) | | LCNEC: 19 (19/41, 46.3%) | | SCC and LCNEC: 1 (1/41, 2.4%) | | NEC: 6 (6/41, 14.6%) | | NET: G2, 4 (4/41, 9.8%) | | Amphicrine carcinoma: 2 (2/41, 4.9%) | | Outcome | Median survival: 11.5 months (range: 2-40 months) | | Median disease-free survival: 12 months (range: 2-48 months) |
|
|
